Enhancement of Macrophage Function by the Antimicrobial Peptide Sublancin Protects Mice from Methicillin-Resistant...

Area of Science:

• Microbiology
• Immunology
• Pharmacology

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) is a significant cause of community and hospital-acquired infections.
• Antimicrobial peptides (AMPs) are a promising class of therapeutic agents against bacterial pathogens.
• Sublancin, a glucosylated AMP from Bacillus subtilis, exhibits antibacterial properties.

Purpose of the Study:

• To investigate the anti-infective role and mechanism of sublancin against MRSA-induced sublethal infection in a mouse model.
• To elucidate how sublancin modulates innate and adaptive immune responses.
• To explore sublancin as a potential therapeutic strategy for S. aureus infections.

Main Methods:

• In vitro assays using RAW264.7 cells and primary macrophages to assess immune modulation.
• In vivo studies using a mouse model of MRSA sublethal infection.
• Analysis of cytokine production (IL-1β, IL-6, TNF-α), nitric oxide levels, phagocytosis, and T cell frequencies (CD4+, CD8+).
• Investigation of signaling pathways including TLR4, NF-κB, and MAPK.

Main Results:

• Sublancin enhanced macrophage phagocytosis and killing activity against MRSA in vitro.
• Sublancin treatment modulated innate immunity by inducing IL-1β, IL-6, TNF-α, and nitric oxide production.
• Oral administration of sublancin increased CD4+ and CD8+ T cell frequencies in vivo.
• Macrophage activation by sublancin was partly dependent on TLR4 and NF-κB/MAPK signaling pathways.
• Sublancin demonstrated protective effects in a mouse model of MRSA infection.

Conclusions:

• Sublancin enhances innate immunity by activating macrophages and promotes T cell responses, offering protection against MRSA infections.
• Macrophages are a key target for sublancin's anti-infective mechanism.
• Sublancin holds potential as a novel therapeutic agent for S. aureus infections by modulating host defense.